Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.
Identifieur interne : 001744 ( PubMed/Corpus ); précédent : 001743; suivant : 001745Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.
Auteurs : D. Deffond ; F. Durif ; M. TournilhacSource :
- Journal of neurology, neurosurgery, and psychiatry [ 0022-3050 ] ; 1993.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Apomorphine.
- chemical , therapeutic use : Apomorphine.
- drug therapy : Parkinson Disease.
- Administration, Sublingual, Aged, Female, Humans, Injections, Subcutaneous, Male, Middle Aged.
Abstract
The efficacy of two routes of apomorphine, subcutaneous (SC) and sublingual (SL), successively administered in 7 Parkinsonian patients with motor fluctuations, was compared in reducing the daily duration of "off" phases. The mean duration of SC and SL treatment was 7.7 and 6.8 months respectively. The mean time spent in "off" phase was 55% after SC and 68% after SL treatment. The mean time before turning "on" after an "off" period was 14 minutes after SC and 28 minutes after SL treatment. Two patients developed stomatitis after SL route. SL apomorphine may be helpful in the treatment of motor fluctuations in PD.
PubMed: 8429309
Links to Exploration step
pubmed:8429309Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.</title><author><name sortKey="Deffond, D" sort="Deffond, D" uniqKey="Deffond D" first="D" last="Deffond">D. Deffond</name><affiliation><nlm:affiliation>Clinique Neurologique, Hôpital Fontmaure, Chamalieres, France.</nlm:affiliation></affiliation></author><author><name sortKey="Durif, F" sort="Durif, F" uniqKey="Durif F" first="F" last="Durif">F. Durif</name></author><author><name sortKey="Tournilhac, M" sort="Tournilhac, M" uniqKey="Tournilhac M" first="M" last="Tournilhac">M. Tournilhac</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1993">1993</date><idno type="RBID">pubmed:8429309</idno><idno type="pmid">8429309</idno><idno type="wicri:Area/PubMed/Corpus">001744</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001744</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.</title><author><name sortKey="Deffond, D" sort="Deffond, D" uniqKey="Deffond D" first="D" last="Deffond">D. Deffond</name><affiliation><nlm:affiliation>Clinique Neurologique, Hôpital Fontmaure, Chamalieres, France.</nlm:affiliation></affiliation></author><author><name sortKey="Durif, F" sort="Durif, F" uniqKey="Durif F" first="F" last="Durif">F. Durif</name></author><author><name sortKey="Tournilhac, M" sort="Tournilhac, M" uniqKey="Tournilhac M" first="M" last="Tournilhac">M. Tournilhac</name></author></analytic><series><title level="j">Journal of neurology, neurosurgery, and psychiatry</title><idno type="ISSN">0022-3050</idno><imprint><date when="1993" type="published">1993</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Sublingual</term><term>Aged</term><term>Apomorphine (administration & dosage)</term><term>Apomorphine (therapeutic use)</term><term>Female</term><term>Humans</term><term>Injections, Subcutaneous</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Apomorphine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Apomorphine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Sublingual</term><term>Aged</term><term>Female</term><term>Humans</term><term>Injections, Subcutaneous</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The efficacy of two routes of apomorphine, subcutaneous (SC) and sublingual (SL), successively administered in 7 Parkinsonian patients with motor fluctuations, was compared in reducing the daily duration of "off" phases. The mean duration of SC and SL treatment was 7.7 and 6.8 months respectively. The mean time spent in "off" phase was 55% after SC and 68% after SL treatment. The mean time before turning "on" after an "off" period was 14 minutes after SC and 28 minutes after SL treatment. Two patients developed stomatitis after SL route. SL apomorphine may be helpful in the treatment of motor fluctuations in PD.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8429309</PMID><DateCreated><Year>1993</Year><Month>03</Month><Day>10</Day></DateCreated><DateCompleted><Year>1993</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3050</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><Issue>1</Issue><PubDate><Year>1993</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J. Neurol. Neurosurg. Psychiatr.</ISOAbbreviation></Journal><ArticleTitle>Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.</ArticleTitle><Pagination><MedlinePgn>101-3</MedlinePgn></Pagination><Abstract><AbstractText>The efficacy of two routes of apomorphine, subcutaneous (SC) and sublingual (SL), successively administered in 7 Parkinsonian patients with motor fluctuations, was compared in reducing the daily duration of "off" phases. The mean duration of SC and SL treatment was 7.7 and 6.8 months respectively. The mean time spent in "off" phase was 55% after SC and 68% after SL treatment. The mean time before turning "on" after an "off" period was 14 minutes after SC and 28 minutes after SL treatment. Two patients developed stomatitis after SL route. SL apomorphine may be helpful in the treatment of motor fluctuations in PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deffond</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinique Neurologique, Hôpital Fontmaure, Chamalieres, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durif</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Tournilhac</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber><NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1988 Apr 23;1(8591):943</RefSource><PMID Version="1">2895868</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1989 Dec;52(12):1440</RefSource><PMID Version="1">2614447</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1990 Feb;53(2):96-101</RefSource><PMID Version="1">2313313</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1988 Feb 20;1(8582):403-6</RefSource><PMID Version="1">2893200</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1991 May;41(5):761-2</RefSource><PMID Version="1">2027501</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 1991 Oct;14(5):432-7</RefSource><PMID Version="1">1742752</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 1991 Dec;14(6):556-61</RefSource><PMID Version="1">1773424</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Rev Neurol (Paris). 1990;146(2):116-22</RefSource><PMID Version="1">2320817</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000286" MajorTopicYN="N">Administration, Sublingual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001058" MajorTopicYN="N">Apomorphine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC1014775</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8429309</ArticleId><ArticleId IdType="pmc">PMC1014775</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001744 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001744 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:8429309
|texte= Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:8429309" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |